Belantamab Mafodotin、硼替佐米和地塞米松与 Daratumumab、硼替佐米和地塞米松在复发/难治性多发性骨髓瘤参与者中的疗效和安全性评价 (DREAMM 7)
DREAMM 7:一项多中心、开放标签、随机 III 期研究,旨在评估 Belantamab Mafodotin、硼替佐米和地塞米松 (B-Vd) 联合疗法与 Daratumumab、硼替佐米和地塞米松联合疗法 (D-Vd) 相比的疗效和安全性) 在患有复发/难治性多发性骨髓瘤的参与者中
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习地点
-
-
-
Beijing、中国、100191
- GSK Investigational Site
-
Beijing、中国、100020
- GSK Investigational Site
-
Changchun、中国、130012
- GSK Investigational Site
-
Guangzhou、中国、510060
- GSK Investigational Site
-
Guangzhou、中国、510515
- GSK Investigational Site
-
Hangzhou、中国、310003
- GSK Investigational Site
-
Jinan、中国、250012
- GSK Investigational Site
-
Nanjing、中国、210008
- GSK Investigational Site
-
Shenyang、中国、110001
- GSK Investigational Site
-
Suzhou、中国、215006
- GSK Investigational Site
-
Tianjin、中国、300020
- GSK Investigational Site
-
Zhengzhou、中国、450052
- GSK Investigational Site
-
-
-
-
-
Jerusalem、以色列、91120
- GSK Investigational Site
-
Kfar Saba、以色列、44281
- GSK Investigational Site
-
Ramat Gan、以色列、52621
- GSK Investigational Site
-
Tel Aviv、以色列、64239
- GSK Investigational Site
-
-
-
-
-
Moscow、俄罗斯、125284
- GSK Investigational Site
-
Nizhny Novgorod、俄罗斯、603126
- GSK Investigational Site
-
Novosibirsk、俄罗斯、630087
- GSK Investigational Site
-
Saint Petersburg、俄罗斯、191024
- GSK Investigational Site
-
Saint Petersburg、俄罗斯、197 089
- GSK Investigational Site
-
Samara、俄罗斯、443021
- GSK Investigational Site
-
Saratov、俄罗斯、410028
- GSK Investigational Site
-
Ufa、俄罗斯、450083
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- GSK Investigational Site
-
Toronto、Ontario、加拿大、M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Joinville、巴西、89201-260
- GSK Investigational Site
-
Natal、巴西、59075-740
- GSK Investigational Site
-
Rio de Janeiro、巴西、22775001
- GSK Investigational Site
-
São Paulo、巴西、04537-080
- GSK Investigational Site
-
São Paulo、巴西、05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、巴西、90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、巴西、88020-210
- GSK Investigational Site
-
-
-
-
-
Athens、希腊、11528
- GSK Investigational Site
-
Thessaloniki、希腊、54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli、East Macedonia and Thrace、希腊、681 00
- GSK Investigational Site
-
-
-
-
-
Cologne、德国、50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm、Baden-Wurttemberg、德国、89081
- GSK Investigational Site
-
-
Bavaria
-
München、Bavaria、德国、81377
- GSK Investigational Site
-
Würzburg、Bavaria、德国、97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf、North Rhine-Westphalia、德国、40225
- GSK Investigational Site
-
-
Thuringia
-
Jena、Thuringia、德国、07747
- GSK Investigational Site
-
-
-
-
-
Bergamo、意大利、24127
- GSK Investigational Site
-
Bologna、意大利、40138
- GSK Investigational Site
-
Brescia、意大利、25123
- GSK Investigational Site
-
Catania、意大利、95123
- GSK Investigational Site
-
Meldola FC、意大利、47014
- GSK Investigational Site
-
Milan、意大利、20133
- GSK Investigational Site
-
Ravenna、意大利、48121
- GSK Investigational Site
-
Roma、意大利、00168
- GSK Investigational Site
-
Siena、意大利、53100
- GSK Investigational Site
-
Torino、意大利、10126
- GSK Investigational Site
-
-
-
-
-
Brno、捷克语、625 00
- GSK Investigational Site
-
Hradec Králové、捷克语、500 05
- GSK Investigational Site
-
Ostrava、捷克语、708 52
- GSK Investigational Site
-
Prague、捷克语、128 08
- GSK Investigational Site
-
-
-
-
-
Christchurch、新西兰、8011
- GSK Investigational Site
-
Dunedin、新西兰、9054
- GSK Investigational Site
-
Takapuna Auckland、新西兰、1309
- GSK Investigational Site
-
Wellington、新西兰、6021
- GSK Investigational Site
-
-
-
-
-
Aichi、日本、467-8602
- GSK Investigational Site
-
Aichi、日本、441-8570
- GSK Investigational Site
-
Aomori、日本、030-8553
- GSK Investigational Site
-
Ehime、日本、790-8524
- GSK Investigational Site
-
Fukuoka、日本、806-8501
- GSK Investigational Site
-
Fukuoka、日本、807-8555
- GSK Investigational Site
-
Fukuoka、日本、810-8563
- GSK Investigational Site
-
Fukuoka、日本、815-8555
- GSK Investigational Site
-
Gifu、日本、503-8502
- GSK Investigational Site
-
Gunma、日本、377-0280
- GSK Investigational Site
-
Hyōgo、日本、670-8540
- GSK Investigational Site
-
Kanagawa、日本、247-8533
- GSK Investigational Site
-
Kanagawa、日本、221-0855
- GSK Investigational Site
-
Kochi、日本、781-8555
- GSK Investigational Site
-
Nagano、日本、392-8510
- GSK Investigational Site
-
Okayama、日本、701-1192
- GSK Investigational Site
-
Osaka、日本、545-8586
- GSK Investigational Site
-
Osaka、日本、530-0012
- GSK Investigational Site
-
Shizuoka、日本、411-8777
- GSK Investigational Site
-
-
-
-
-
Roeselare、比利时、8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette、Brussels Capital、比利时、1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert、Brussels Capital、比利时、1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、比利时、9000
- GSK Investigational Site
-
-
-
-
-
Amiens、法国、80054
- GSK Investigational Site
-
Caen、法国、14033
- GSK Investigational Site
-
Nice、法国、06200
- GSK Investigational Site
-
Paris、法国、75651
- GSK Investigational Site
-
Rennes、法国、35033
- GSK Investigational Site
-
-
-
-
-
Chorzów、波兰、41-500
- GSK Investigational Site
-
Krakow、波兰、30510
- GSK Investigational Site
-
Lodz、波兰、93-513
- GSK Investigational Site
-
Lublin、波兰、20-081
- GSK Investigational Site
-
Lublin、波兰、20-090
- GSK Investigational Site
-
Nowy Sącz、波兰、33-300
- GSK Investigational Site
-
Poznan、波兰、60-569
- GSK Investigational Site
-
Warsaw、波兰、02-781
- GSK Investigational Site
-
-
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- GSK Investigational Site
-
Liverpool、New South Wales、澳大利亚、2170
- GSK Investigational Site
-
Newcastle、New South Wales、澳大利亚、2298
- GSK Investigational Site
-
St Leonards、New South Wales、澳大利亚、2065
- GSK Investigational Site
-
Wollongong、New South Wales、澳大利亚、2500
- GSK Investigational Site
-
-
Queensland
-
Benowa、Queensland、澳大利亚、4217
- GSK Investigational Site
-
Herston、Queensland、澳大利亚、4029
- GSK Investigational Site
-
-
South Australia
-
Ashford、South Australia、澳大利亚、5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill、Victoria、澳大利亚、3128
- GSK Investigational Site
-
Heidelberg、Victoria、澳大利亚、3084
- GSK Investigational Site
-
Melbourne、Victoria、澳大利亚、3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch、Western Australia、澳大利亚、6150
- GSK Investigational Site
-
Nedlands、Western Australia、澳大利亚、6009
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma、Arizona、美国、85364
- GSK Investigational Site
-
-
Kansas
-
Mission、Kansas、美国、66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver、North Carolina、美国、80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash、Ohio、美国、45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler、Texas、美国、75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke、Virginia、美国、24014
- GSK Investigational Site
-
-
-
-
-
Bournemouth、英国、BH7 7DW
- GSK Investigational Site
-
Cardiff、英国、CF14 4XW
- GSK Investigational Site
-
Dundee、英国、DD1 9SY
- GSK Investigational Site
-
Leicester、英国、LE1 5WW
- GSK Investigational Site
-
London、英国、W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent、英国、ST4 6QG
- GSK Investigational Site
-
Sutton、英国、SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Groningen、荷兰、9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht、South Holland、荷兰、3318 AT
- GSK Investigational Site
-
-
-
-
-
Barcelona、西班牙、08035
- GSK Investigational Site
-
Barcelona、西班牙、08916
- GSK Investigational Site
-
Cáceres、西班牙、10003
- GSK Investigational Site
-
Gijón、西班牙、33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega、西班牙、08908
- GSK Investigational Site
-
MOstoles Madrid、西班牙、28933
- GSK Investigational Site
-
Madrid、西班牙、28007
- GSK Investigational Site
-
Madrid、西班牙、31008
- GSK Investigational Site
-
Murcia、西班牙、30008
- GSK Investigational Site
-
PamplonaNavarra、西班牙、31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr、西班牙、28223
- GSK Investigational Site
-
Salamanca、西班牙、37007
- GSK Investigational Site
-
-
-
-
-
Pusan、韩国、49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do、韩国、13620
- GSK Investigational Site
-
Seoul、韩国、06351
- GSK Investigational Site
-
Seoul、韩国、06591
- GSK Investigational Site
-
Ulsan、韩国、44033
- GSK Investigational Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Belantamab mafodotin 和硼替佐米加地塞米松(A 组)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
有源比较器:Daratumumab 和硼替佐米加地塞米松(B 组)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free Survival (PFS)
大体时间:Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
眼科检查中出现异常眼部发现的参与者人数
大体时间:长达 73 个月
|
长达 73 个月
|
|
|
Complete Response Rate (CRR)
大体时间:Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
大体时间:Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
大体时间:Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
大体时间:Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
大体时间:Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
大体时间:Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
大体时间:Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
大体时间:Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
大体时间:Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
大体时间:Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
大体时间:Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
大体时间:Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
大体时间:Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
大体时间:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
大体时间:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
大体时间:Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
大体时间:Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
大体时间:Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
大体时间:Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
大体时间:Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
大体时间:Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
合作者和调查者
调查人员
- 研究主任:GSK Clinical Trials、GlaxoSmithKline
出版物和有用的链接
一般刊物
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 207503
- 2018 (美国 NIH 拨款/合同)
- 2018-003993-29 (注册表标识符:EudraCT (EU))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.